Ernie Tremblay has obtained over 25 years of experience in analyzing developments in medical and health technologies. Before turning to biotech investing, Tremblay wrote over 100 publications about topics such as arthritis, diabetes, rheumatology, dermatology, and Alzheimer’s. Furthermore, he has edited books about medical therapies, science, and microbiology. The knowledge of how the FDA operates and the science behind new drugs lead him to begin investing in the biotech industry. In 2012, he published a Three-Phase System to identify upcoming drugs and aid investors in finding profit off the stock. One of the first successes of this system came from Aegerion Pharmaceuticals Inc. (AEGR) on a drug to treat a fatal and rare type of blood disease. The stock had a 346% total return in eight months. Tremblay is now a contributor at Money Morning as a specialist in biotech investing and writes Biotech Insider Alert. Since 2012, he has been a guest editor at Money Map Press.